Q2 EPS Estimate for ORIC Pharmaceuticals Boosted by Analyst

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Equities researchers at Wedbush increased their Q2 2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a report released on Monday, May 5th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.48) per share for the quarter, up from their previous estimate of ($0.49). Wedbush currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.17) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.84) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.90) EPS and FY2028 earnings at ($1.24) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.09.

Several other analysts have also recently commented on ORIC. JPMorgan Chase & Co. raised their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday. Oppenheimer cut their target price on ORIC Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research report on Monday, May 5th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $19.17.

ORIC Pharmaceuticals Trading Down 4.5 %

NASDAQ:ORIC opened at $5.08 on Thursday. ORIC Pharmaceuticals has a 12-month low of $3.90 and a 12-month high of $14.67. The stock’s 50 day simple moving average is $5.90 and its 200-day simple moving average is $8.07. The firm has a market cap of $361.13 million, a P/E ratio of -2.79 and a beta of 1.37.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS acquired a new stake in shares of ORIC Pharmaceuticals in the fourth quarter valued at approximately $50,000. Arizona State Retirement System acquired a new stake in shares of ORIC Pharmaceuticals during the first quarter valued at $56,000. BNP Paribas Financial Markets purchased a new stake in ORIC Pharmaceuticals during the 4th quarter worth about $71,000. PNC Financial Services Group Inc. lifted its holdings in ORIC Pharmaceuticals by 22.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock valued at $109,000 after purchasing an additional 2,520 shares in the last quarter. Finally, Legato Capital Management LLC purchased a new stake in shares of ORIC Pharmaceuticals during the first quarter worth about $109,000. 95.05% of the stock is owned by institutional investors and hedge funds.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.